BioInvent International (BATS-CHIXE:BINVS) - Aandelenkoers, Nieuws & Analyse

BINVS Overzicht aandelen

A clinical-stage company, discovers, researches, and develops novel immuno-modulatory antibodies for the treatment of cancer in Sweden, Europe, the United States, and internationally. Meer informatie

BINVS fundamentele analyse
Sneeuwvlok Score
Waardering	4/6
Toekomstige groei	5/6
Prestaties in het verleden	0/6
Financiële gezondheid	5/6
Dividenden	0/6

Beloningen

Verhandeld tegen 65.4% onder onze schatting van de reële waarde

De winst zal naar verwachting met 64.4% per jaar groeien

Risicoanalyse

Aandelen zijn zeer illiquide

Aandeelhouders zijn het afgelopen jaar verwaterd

BioInvent International AB (publ) Concurrenten

Avacta Group

AIM:AVCT

UK£179.3m

Bioventix

AIM:BVXP

UK£195.7m

Tissue Regenix Group

AIM:TRX

UK£40.6m

Arecor Therapeutics

AIM:AREC

UK£28.3m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor BioInvent International
Historische aandelenkoersen
Huidige aandelenkoers	SEK 34.75
52 Week Hoogtepunt	SEK 39.45
52 Week Laag	SEK 34.70
Bèta	0.30
11 maand verandering	0%
3 maanden verandering	-3.87%
1 Jaar Verandering	n/a
33 jaar verandering	-4.40%
5 jaar verandering	-31.86%
Verandering sinds IPO	-43.27%

Recent nieuws en updates

Recent updates

Rendement voor aandeelhouders

	BINVS	GB Biotechs	GB Markt
7D	0%	2.0%	1.7%
1Y	n/a	-17.5%	8.3%

Rendement versus industrie: Er zijn onvoldoende gegevens om te bepalen hoe BINVS presteerde ten opzichte van de UK Biotechs.

Rendement versus markt: Er zijn onvoldoende gegevens om te bepalen hoe BINVS presteerde ten opzichte van de UK markt.

Prijsvolatiliteit

Is BINVS's price volatile compared to industry and market?
BINVS volatility
BINVS Average Weekly Movement	n/a
Biotechs Industry Average Movement	9.7%
Market Average Movement	4.8%
10% most volatile stocks in GB Market	10.3%
10% least volatile stocks in GB Market	2.6%

Stabiele aandelenkoers: BINVS heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: Onvoldoende gegevens om de volatiliteitsverandering van BINVS in het afgelopen jaar te bepalen.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
1996	93	Martin Welschof	www.bioinvent.com

BioInvent International AB (publ) Samenvatting

Hoe verhouden de winst en inkomsten van BioInvent International zich tot de beurswaarde?
BINVS fundamentele statistieken
Marktkapitalisatie	SEK 2.07b
Inkomsten(TTM)	-SEK 42.93m
Inkomsten(TTM)	SEK 310.39m

6.7x

P/S-verhouding

-48.3x

Koers/Winstverhouding

Is BINVS overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
BINVS resultatenrekening (TTM)
Inkomsten	SEK 310.39m
Kosten van inkomsten	SEK 0
Brutowinst	SEK 310.39m
Overige uitgaven	SEK 353.32m
Inkomsten	-SEK 42.93m

Laatst gerapporteerde inkomsten

Sep 30, 2022

Volgende inkomensdatum

Feb 22, 2023

Winst per aandeel (EPS)	-0.65
Brutomarge	100.00%
Nettowinstmarge	-13.83%
Schuld/Eigen Vermogen Verhouding	0%

Hoe presteerde BINVS op de lange termijn?

Bekijk historische prestaties en vergelijking

BINVS Overzicht aandelen

Beloningen

Risicoanalyse

BioInvent International AB (publ) Concurrenten

AIM:AVCT

UK£179.3m

AIM:BVXP

UK£195.7m

AIM:TRX

UK£40.6m

AIM:AREC

UK£28.3m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

BioInvent International AB (publ) to Report Q3, 2025 Results on Oct 29, 2025

Bioinvent and Transgene’S Oncolytic Virus BT-001 Shows Promising Antitumor Activity in Ongoing Phase 1/2A Trial in Solid Tumors That Failed Previous Treatments

Bioinvent International AB Announces the Enrollment of the First Patient in Triple Combination Arm of Phase 1/2A Study, Bi-1206, Rituximab and Calquence(R) for the Treatment of Non-Hodgkin's Lymphoma

Bioinvent Announces Additional Positive Efficacy Data with Single Agent BI-1808 from the Phase 2a anti-TNFR2 program

BioInvent Receives Notice of Allowance from USPTO for BI-1910 Patent Application

Bioinvent International AB Presents Poster Highlighting Model-Informed Early Clinical Development of Anti-TNFR2 Agent BI-1808 At PAGE 2024

Recent updates

BioInvent International AB (publ) to Report Q3, 2025 Results on Oct 29, 2025

Bioinvent and Transgene’S Oncolytic Virus BT-001 Shows Promising Antitumor Activity in Ongoing Phase 1/2A Trial in Solid Tumors That Failed Previous Treatments

Bioinvent International AB Announces the Enrollment of the First Patient in Triple Combination Arm of Phase 1/2A Study, Bi-1206, Rituximab and Calquence(R) for the Treatment of Non-Hodgkin's Lymphoma

Bioinvent Announces Additional Positive Efficacy Data with Single Agent BI-1808 from the Phase 2a anti-TNFR2 program

BioInvent Receives Notice of Allowance from USPTO for BI-1910 Patent Application

Bioinvent International AB Presents Poster Highlighting Model-Informed Early Clinical Development of Anti-TNFR2 Agent BI-1808 At PAGE 2024

BioInvent International Gains Patent for BI-1808 in China

BioInvent International AB Presents Promising Clinical Efficacy and Safety for Anti-Tnfr2 Agent BI-1808 At Asco 2024

Bioinvent to Present Additional Promising Phase 1/2A Data At EHA 2024 for BI-1206 with rituximab in NHL

BioInvent International AB (publ) to Report Nine Months, 2024 Results on Oct 31, 2024

BioInvent International AB (publ), Annual General Meeting, May 03, 2024

BioInvent International AB (publ) to Report Fiscal Year 2023 Results on Feb 22, 2024

BioInvent International AB (publ) Presents Positive First Clinical Data on Anti-FcyRIIB Antibody BI-1607

Bioinvent Enrolls First Patient in Phase 1/2A Clinical Trial with TNFR2 Antibody BI-1910

BioInvent Presents Positive Data at SITC from Clinical Phase 1/2a Trial of BI-1808 as Single Agent

BioInvent Presents Preclinical Data at SITC Providing Clear Evidence of the Potential of Anti-TNFR2 Antibody BI-1910

Bioinvent International AB Recruits First Patient in Single Agent Phase 2a Part of its Phase 1/2a Trial of its First-in-Class Anti-TNFR2 Antibody BI-1808 in Advanced Malignancies

BioInvent International AB Initiates Subcutaneous Arm of Phase 1/2 Trial with BI-1206 in Solid Tumors

BioInvent International AB (publ) Reports Strong Interim Safety Data and Early Signs of Efficacy in Phase 1/2a Trial with Anti-TNFR2 Antibody BI-1808 in Advanced Malignancies

BioInvent International AB Announces Abstract Presentation of BI-1206 At the 17th International Conference of Malignant Lymphoma 2023

BioInvent International AB Announces Additional Efficacy Data from Intravenous Part of Phase 1/2 Trial with BI-1206 in Solid Tumors

BioInvent Ready for Combination Studies with BT-001

BioInvent International AB (Publ) Appoints of Ingunn Munch Lindvig as Senior Vice President Regulatory Affairs

BioInvent International AB (publ), Annual General Meeting, Apr 27, 2023

Bioinvent International AB Provides Update on Its Clinical and Pre-Clinical Pipeline, Including an Update on Its Lead Drug Candidate, the Novel Anti-Fc?RIIB Antibody Bi-1206

BioInvent International AB (publ) Receives FDA IND Approval for Anti-FcyRIIB Antibody BI-1607